

ELCO-P

Early Lung Cancer Treatment Pathway Optimisation

Christian Muehlendyck
cmuehlen@ITS.JNJ.COM
Johnson&Johnson




Projections of Lung Cancer Incidence by 2035

Population-Based Study in 40 Countries Worldwide

- LC incidence is expected to continue increasing through 2035 in most countries, making LC a major public health challenge worldwide.
- LC epidemiology varies significantly across countries due to factors such as population aging, evolving risk factors, and gender differences. The incidence rates among females are predicted to increase dramatically.
- LC therapies are evolving rapidly, but there is **no standardized approach or clear guidelines for treating the emerging patient cohorts.**

source: BMS, 2015




EUROPE'S BEATING CANCER PLAN

4 in 10 cancer cases are preventable

Unless we act now, cases will double by 2035


European Commission | #EUCancerPlan

The graphic features a red background with a white silhouette of a person running. Below the title, there are two rows of ribbons: the top row has four blue ribbons and two white ribbons, and the bottom row has two white ribbons and four blue ribbons. To the right of the ribbons is a circular icon with a person silhouette and the text 'x2'. At the bottom, there is the European Commission logo and the hashtag #EUCancerPlan.




source: BMS, 2015

Increased Lung Cancer Screening in Europe



=> Significant increase in patients diagnosed with Early Lung Cancer

ELCO-P Vision and Solution



Optimizing the clinical outcomes for patients diagnosed with early-stage lung cancer by standardization of the treatment pathway & development of a continuous improvement plan

ELCO-P Deliverables / Outcomes

Guideline Revision & Patient Pathway Optimization

Defining pathways for Stage IA-IIIB patients

Table 27 Stage distributions of diagnosed cases by presentation or LDCT screening (per 100,000 ever smokers 55-80 years)

Screening design	NSCLC							SCLC	
	IA1	IA2	IA3	IB	II	III	IV	Ltd	Ext
No screening		1,440 (0%)	600 (2%)	1,320 (5%)	3,480 (14%)	5,760 (22%)	12,680 (50%)	1,840 (30%)	4,480 (70%)
Single	640 (3%)	3,080 (13%)	1,120 (4%)	1,440 (6%)	3,200 (13%)	5,760 (22%)	10,360 (39%)	1,840 (30%)	4,480 (70%)
Triple	1,480 (6%)	3,440 (14%)	1,240 (4%)	1,400 (6%)	3,400 (13%)	6,120 (24%)	8,760 (32%)	2,600 (42%)	3,720 (58%)
Annual	4,520 (16%)	7,960 (29%)	1,960 (7%)	920 (3%)	2,760 (10%)	4,760 (17%)	5,160 (18%)	3,920 (63%)	2,400 (37%)
Biennial	2,920 (11%)	5,880 (22%)	2,280 (8%)	920 (3%)	3,400 (12%)	5,240 (19%)	6,760 (24%)	2,680 (42%)	3,640 (58%)

Peters J, Snowsill T, Griffin E, Robinson S, Jubane A, Hyde C. Health Technology Assessment (In press)
(Interim unaudited report: <https://view.health-screening-recommendations.service.gov.uk/lung-cancer/>)

Peters J., Snowsill T., Griffin E., Robinson S., Juhaeri A., Hyde C.

Title: *Health Technology Assessment*

Status: *In press*

- Review current guidelines (GRADE analysis of the supporting evidence)
- Analyze the data based on mutation status
- Implement a shared registry to monitor recurrence rates and PROMs
- Develop tailored guidelines for subpopulations without and with mutations
- Leveraging existing data infrastructures from clinical societies and federated solutions
- Develop a predictive AI responsiveness model to accurately forecast patient responses and optimize treatment strategies



ELCO-P Impact



1. For Health Systems and Practitioners:

- Clear Treatment Guidelines for optimal treatment of increasing new cohort of early LC patients

=> Outcome improvement / Cost & Resource Reduction

2. For Patients:

- Better Care & Clinical Outcome



3. For Policymakers & Regulators:

- Better decision making, quality improvement
- 



In-kind contributions expected from companies

- Lung Cancer Diagnosis & Treatment
 - Medical & Real World Evidence
 - Regulatory and Policy Engagements
 - Evaluation and Dissemination
 - Sustainability Planning
- 
- 
- 

ELCO-P Data

Expected duration / budget

- 48-60 months
- Budget: €10-15mln from industry to be mirrored by IHI

Partners

- Academic Lead: University of Calabria, Prof. F. Melfi
 - Industry Lead: J&J MedTech
 - Public Partners: TBD
 - Industry partners: TBD
-
- **Wanted:**
 - Industry partners with expertise in: LC Treatment: MedTech, Pharma,...
 - Academic Partners with expertise in LC Treatment, Digital, Patient Organisation,...

Contact

- Carmen Di Palma cdipalma@its.jnj.com
- Thomas Stacy TStacy2@its.jnj.com
- Christian Muehlendyck Cmuehlen@its.jnj.com